In August 2026, the U.S. FDA expanded the indication for Mounjaro (tirzepatide). In the United States, it can now also be used to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high cardiovascular risk.

The decision was driven primarily by the large SURPASS-CVOT trial, which compared tirzepatide with dulaglutide, a GLP-1 receptor agonist with established cardiovascular benefit.

What exactly did the FDA approve?

The new U.S. indication covers reduction in the risk of MACE – major adverse cardiovascular events, a composite that includes cardiovascular death, nonfatal myocardial infarction and nonfatal stroke.

This goes beyond glucose lowering or body-weight outcomes. The U.S. label for Mounjaro now also includes cardiovascular risk reduction in high-risk adults with type 2 diabetes.

The key SURPASS-CVOT trial

SURPASS-CVOT is one of the largest tirzepatide studies to date. It randomized 13,299 participants with type 2 diabetes and established atherosclerotic cardiovascular disease. Tirzepatide was compared with dulaglutide, with a median follow-up of more than four years.

The primary MACE endpoint occurred in 12.2% of participants receiving tirzepatide and 13.1% receiving dulaglutide. The hazard ratio was 0.92.

The statistical interpretation matters: the trial demonstrated noninferiority, meaning tirzepatide was not worse than dulaglutide for the primary cardiovascular endpoint. Formal superiority over dulaglutide was not established for that endpoint.

Why does the dulaglutide comparison matter?

Many cardiovascular outcome trials historically compared treatment with placebo. SURPASS-CVOT instead used an active comparator with established cardiovascular evidence. This set a higher clinical benchmark and the study met its primary noninferiority objective.

Tirzepatide targets both GIP and GLP-1

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates two incretin signaling pathways and has effects on glycemic control, food intake and body weight.

The 2026 regulatory update shifts attention further toward long-term clinical outcomes rather than glucose and body weight alone.

What did the safety data show?

The overall safety profile was consistent with the known profile of tirzepatide. The most commonly reported adverse effects were gastrointestinal, including nausea, diarrhea and vomiting. Current U.S. prescribing information also includes additional warnings, contraindications and safety information.

Does this automatically change the indication in Europe?

No. The August 28, 2026 decision is a U.S. FDA action. European indications are governed separately by the European Medicines Agency and the European Commission.

What does this mean for tirzepatide research?

SURPASS-CVOT illustrates a broader shift in incretin research toward hard clinical endpoints such as myocardial infarction, stroke and cardiovascular death.

The expanded FDA indication is an important regulatory milestone, but it should not be interpreted as proof that tirzepatide is superior to all GLP-1 receptor agonists. SURPASS-CVOT established noninferiority to dulaglutide for the primary cardiovascular endpoint.

Summary

• In August 2026, the FDA expanded the U.S. Mounjaro indication to include reduction of major cardiovascular events in selected adults with type 2 diabetes.
• SURPASS-CVOT enrolled 13,299 participants.
• MACE occurred in 12.2% vs. 13.1%; HR 0.92.
• The trial demonstrated noninferiority, not formal superiority, versus dulaglutide for the primary endpoint.
• The U.S. indication does not automatically apply in the European Union.

Information current to September 2026. This article is for educational and informational purposes only. It is not medical advice and does not replace the official prescribing information for an approved medicine. Clinical evidence from an approved medicine cannot automatically be extrapolated to research materials.